HRTX - Heron Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Heron Therapeutics, Inc.

4242 Campus Point Court
Suite 200
San Diego, CA 92121
United States
858-251-4400
http://www.herontx.com

SectorHealthcare
IndustryDrug Manufacturers - Major
Full Time Employees139

Key Executives

NameTitlePayExercisedAge
Dr. Barry D. Quart Pharm.D.Chief Exec. Officer & Director795.59k76.26k60
Mr. Robert H. RosenPres & Director787.63k4.82M61
Ms. Kimberly J. ManhardExec. VP of Drug Devel.544.74kN/A57
Mr. Robert E. HoffmanChief Financial Officer and Sr. VP of Fin.N/AN/A51
Ms. Jennifer CapuzeloAssociate Director of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Heron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single subcutaneous injection. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens. The company is also developing CINVANTI (HTX-019), a neurokinin-1 receptor antagonist for the prevention of CINV; and HTX-011, which is in Phase II clinical development for the prevention of post-operative pain. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Corporate Governance

Heron Therapeutics, Inc.’s ISS Governance QualityScore as of February 1, 2018 is 7. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.